ClinicalTrials.gg
RecruitingNCT07153692Updated Sep 4, 2025

Clinical Efficacy and Mechanism of tDCS for Dysphagia in PD

An interventional study of tDCS and Conventional Dysphagia Treatment in Parkinson's Disease and Parkinsonism and Dysphagia, sponsored by Wang Ping. Recruiting at 1 site in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Wang Ping · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 279 studies in Parkinson Disease with a site in China — 128 open to participants now, 135 under way, 3 of them phase 3. Parkinson Disease · China.

Planned enrollment
89th of 211
58 · median 47
Started
2025
with 32 others
No phase
115 of 279
57 open now
Primary completion
2029-12
later than 128 of 134 live
Registered
220th of 279
by date

Among the 279 studies in Parkinson Disease with a site in China, this one is the 89th largest by planned enrollment of the 211 interventional ones that give a count, is one of 33 that started in 2025, is one of 115 with no phase, reaches primary completion later than 128 of the 134 other live ones, and was the 220th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

128 of the 279 studies in Parkinson Disease with a site in China are open now. Recruiting first, the newest first:

123 more — sign in →

All 128 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 279 studies in Parkinson Disease with a site in China, or all of them as a file.
02

Study summary

This study aims to verify transcranial direct current stimulation(tDCS) efficacy for Parkinson's disease (PD)-related dysphagia and its mechanism. Subjects are randomly split into two groups: control (sham tDCS + conventional dysphagia treatment) and experimental (real tDCS + conventional treatment).

Assessments will be conducted at baseline, after the completion of intervention, and at the 3-month follow-up. Swallowing function will be evaluated via gold-standard videofluoroscopic swallowing study (VFSS) and scales. Resting-state functional magnetic resonance imaging (rs-fMRI) or functional near-infrared spectroscopy (fNIRS) will be measures for tracking changes in abnormal brain regions/networks.

Correlations between swallowing recovery and brain function changes, plus group imaging differences, will reveal tDCS's neurophysiological mechanism.

Read the detailed description

This study aims to verify the efficacy of tDCS in treating dysphagia in PD and explore its mechanism. Subjects are randomly divided into two groups: the control group receives sham tDCS as well as the conventional dysphagia treatment, while the experimental group undergoes real tDCS combined with conventional dysphagia treatment.

All subjects will be evaluated before treatment, after treatment, and 3 months later (follow-up). Swallowing function in both groups will be assessed using the gold standard VFSS and swallowing scales. Additionally, techniques including amplitude of low frequency fluctuation (ALFF) and functional connectivity (FC) in rs-fMRI or fNIRS will be used to observe changes in abnormal brain regions and brain network connectivity before and after treatment in both groups.

This study will also explore the correlation between swallowing function recovery and the alteration of brain function, compare the imaging differences between the two groups, and thereby reveal the neurophysiological mechanism underlying tDCS in the treatment of PD-related dysphagia.

03

Conditions studied

  • Parkinson's Disease and Parkinsonism
  • Dysphagia

Keywords

  • Parkinson's disease
  • Atypical Parkinsonian Syndromes
  • dysphagia
  • tDCS
  • VFSS
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meet the Chinese Diagnostic Criteria for Parkinson's Disease (2016) or MDS Diagnostic Criteria for Multiple System Atrophy or Progressive Supranuclear Palsy;
  • VFSS examination indicates dysphagia;
  • (MMSE) score >23;
  • Willing to cooperate with the study and sign the form;

Exclusion criteria

Exclusion Criteria:

  • Comorbid with other diseases that cause dysphagia;
  • Comorbid with pneumonia, or severe cardiac/renal insufficiency;
  • Having metal implants in the body
  • With cognitive impairment or inability to cooperate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
58 participants (estimated)

Study arms

  • Experimental
    real tDCS group

    tDCS Treatment Protocol The anode of the electrode pad will be placed on the swallowing sensorimotor cortex (S1/M1). The cathode will be placed on the contralateral supraorbital margin. The S1/M1 areas of the left and right hemispheres will be stimulated alternately, with a current intensity of 1.6mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere). Conventional Dysphagia Treatment 1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.; 2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;

    Device: tDCS · Behavioral: Conventional Dysphagia Treatment

  • Sham comparator
    sham tDCS group

    Sham tDCS Treatment Protocol The electrode positions and treatment frequency of sham tDCS will be the same as those of real tDCS. The current is 0.05 mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere). Conventional Dysphagia Treatment 1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.; 2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;

    Behavioral: Conventional Dysphagia Treatment · Device: sham tDCS

Interventions

  • DevicetDCS

    The IS200 intelligent electrical stimulator, manufactured in Chengdu, Sichuan, will be used. The electrode pads are 4cm × 6cm in size. The anode of the electrode pad will be placed on the swallowing sensorimotor cortex (S1/M1). The specific positioning will follow the international 10-20 electroencephalographic system: the left S1/M1 area is located at the midpoint of the line connecting C3 and T3 in the left hemisphere; the right S1/M1 area is located at the midpoint of the line connecting C4 and T4 in the right hemisphere. The cathode will be placed on the contralateral supraorbital margin. The S1/M1 areas of the left and right hemispheres will be stimulated alternately, with a current intensity of 1.6mA. The treatment will be given once daily, 20 minutes per session, 5 times a week, for 2 consecutive weeks, totaling 10 sessions (5 sessions for each hemisphere).

  • BehavioralConventional Dysphagia Treatment

    1. Training for perioral muscles, tongue sensory and motor functions, including ice cotton swab stimulation, gustatory stimulation, tongue muscle movement training, etc.; 2. Airway protection training, including Mendelsohn maneuver, supraglottic swallow training, etc.;

  • Devicesham tDCS

    According to previous literature, the electrode positions and treatment frequency of sham tDCS will be the same as those of real tDCS. The current will be adjusted to 0.05mA.

06

What researchers measure

Primary outcomes

  1. Rosenbek Penetration-Aspiration Scale (PAS):

    Scored 1-8, with higher scores indicating poorer swallowing safety. 1. Level 1: The bolus does not enter the airway; it remains entirely within the oral cavity or pharynx and is propelled normally. 2. Level 2: The bolus enters the supraglottic area (e.g., vallecula) but does not touch the vocal cords, and is completely cleared (e.g., via swallowing or coughing). 3. Level 3: The bolus enters the supraglottic area without touching the vocal cords, but residue remains (not fully cleared). 4. Level 4: The bolus touches the vocal cords but does not enter the subglottic airway, and is completely cleared. 5. Level 5: The bolus touches the vocal cords without entering the subglottic airway, but residue remains. 6. Level 6: The bolus enters the subglottic airway (into the trachea) but is completely cleared by the patient (e.g., via coughing). 7. Level 7: The bolus enters the subglottic airway; the patient exhibits protective responses (e.g., coughing) but cannot fully clear it, leaving

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  2. Videofluoroscopic Dysphagia Scale (VDS)

    14 items in total, including 7 items for oral-phase swallowing function and 7 for pharyngeal-phase function, used to assess overall swallowing function;

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  3. oral residue

    Post-swallow residue was scored 0-3, with higher scores indicating more food residue and lower swallowing efficiency

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  4. Amplitude of Low Frequency Fluctuation (ALFF)

    ALFF focuses on the low-frequency components of these HbO/HbR time series. It is defined as the average amplitude of hemodynamic signal fluctuations within a specific low-frequency range (typically 0.01-0.1 Hz, though the exact band may vary by study). This range is chosen because it captures slow, spontaneous oscillations in cerebral blood flow and oxygenation, which are hypothesized to reflect synchronized neural activity across brain regions (e.g., default mode network, sensorimotor networks). Mathematically, ALFF quantifies the "strength" of these low-frequency oscillations: a higher ALFF value indicates more prominent or intense fluctuations in the target frequency band, suggesting greater spontaneous hemodynamic (and thus neural) activity in that brain region.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  5. Functional Connectivity (FC)

    Functional Connectivity (FC) refers to the statistical association or synchronization between spontaneous hemodynamic signals from different cortical regions, reflecting the coordinated activity of spatially distinct brain areas. It quantifies how closely the neural activity (inferred from blood oxygenation changes) in one brain region correlates with that in another, providing insights into the integration of brain networks.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  6. vellaculae residue

    The residue amount was rated on a scale from 0 to 3: 0 indicates that no residue was visible, 1 indicates mild residue(the level of contrasted material constituted less than 25% of the height of the structure), 2 indicates moderate residue (the level of contrasted material constituted between 25 and 50%of the height of the structure), and 3 indicates severe residue(the level was higher than 50% of the height of the structure).

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  7. pyriform sinuses residue

    The residue amount was rated on a scale from 0 to 3: 0 indicates that no residue was visible, 1 indicates mild residue(the level of contrasted material constituted less than 25% of the height of the structure), 2 indicates moderate residue (the level of contrasted material constituted between 25 and 50%of the height of the structure), and 3 indicates severe residue(the level was higher than 50% of the height of the structure).

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

Secondary outcomes

  1. temporal indicators

    TT, PTT, LVCrt, and so on.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  2. spatial indicators

    hyoid bone advancement, hyoid bone elevation, PCR

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  3. Swallowing Disorder Questionnaire (SDQ)

    A swallowing function screening scale with 15 items, scored up to 44.5; higher scores indicate more severe dysphagia.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  4. Functional Oral Intake Scale (FOIS)

    7 levels in total, with Level 1 indicating the most severe feeding impairment and Level 7 indicating normal function.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

Other outcomes

  1. Unified Parkinson's Disease Rating Scale-III (UPDRS-III)

    14 items, scored up to 56; higher scores indicate more severe motor dysfunction.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  2. Swallowing Quality of Life Questionnaire (SWAL-QOL)

    The SWAL-QOL is a patient-reported outcome tool designed to assess the impact of oropharyngeal dysphagia on health-related quality of life. It Comprises 44 items. it evaluates both subjective experiences (e.g., psychological burden) and clinical symptoms (e.g., choking, food sticking) through self-reported responses.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

  3. Non-Motor Symptoms Scale (NMSS) for Parkinson's Disease

    30 items, scored up to 210; higher scores indicate more severe non-motor symptoms.

    Time frame: at baseline, after the completion of 10 days of intervention, at the 3-month follow-up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Ding X, Gao J, Xie C, Xiong B, Wu S, Cen Z, Lou Y, Lou D, Xie F, Luo W. Prevalence and clinical correlation of dysphagia in Parkinson disease: a study on Chinese patients. Eur J Clin Nutr. 2018 Jan;72(1):82-86. doi: 10.1038/ejcn.2017.100. Epub 2017 Jul 12. PubMed 28699630 ↗
  • Henry KA, Singh R, Zhang N, Lyons MK, McNett K, Neal MT, Mehta SH. Effect of STN/GPi DBS on swallowing function in Parkinson's disease as assessed by Video fluoroscopy: A retrospective study. Parkinsonism Relat Disord. 2022 Oct;103:136-140. doi: 10.1016/j.parkreldis.2022.08.017. Epub 2022 Sep 11. PubMed 36115199 ↗
  • Wang P, Wang B, Chen X, Xiong B, Xie F, Wu S, Tang Y, Chen S, Ding X, Liu P, Luo W. Six-Year Follow-Up of Dysphagia in Patients with Parkinson's Disease. Dysphagia. 2022 Oct;37(5):1271-1278. doi: 10.1007/s00455-021-10387-0. Epub 2021 Nov 26. PubMed 34826007 ↗
  • Gandhi P, Steele CM. Effectiveness of Interventions for Dysphagia in Parkinson Disease: A Systematic Review. Am J Speech Lang Pathol. 2022 Jan 18;31(1):463-485. doi: 10.1044/2021_AJSLP-21-00145. Epub 2021 Dec 10. PubMed 34890260 ↗
  • Dashtelei AA, Nitsche MA, Salehinejad MA, Habibi AH, Bakhtyiari J, Khatoonabadi AR. Adjunctive transcranial direct current stimulation to improve swallowing functions in Parkinson's disease. EXCLI J. 2024 Jan 18;23:95-107. doi: 10.17179/excli2023-6496. eCollection 2024. PubMed 38487086 ↗

Individual participant data

Plan to share: No — The IPD sharing plan includes making the statistical results of the data publicly available to other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2029, 53 months after the start.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 53 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Sep 4, 2025
StartActual
Jul 17, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Mar 31, 2030
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07153692
Lead sponsor
Wang Ping
Responsible party
Wang Ping (senior therapist, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Sponsor-investigator
First posted
Sep 4, 2025
Start date
Jul 17, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Sep 4, 2025

Study contacts

Ping Wang, MS
Contact
wangping6288@zju.edu.cn
15158113194
Bo Wang, MD
Contact
wangke1121@zju.edu.cn
Ping Wang
principal investigator · Second Affiliated Hospital of Zhejiang University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion